Ms. Anastasi provides leadership to create and foster priority relationships in the medical device and diagnostic marketplace, developing customized programs to meet medical device client needs. She has over twenty five years of experience in the medical device industry, with over fifteen years specifically focused on global medical device strategic consulting.
Prior to joining the company in 2007, she held senior management roles for medical device companies focused in orthopedics, cardiovascular, general hospital, and general surgical devices. In diagnostics, she held senior positions at companies involved in the development of infectious disease and genetic-based products.
A career in medical devices spanning 28 years, including various CEO and senior leadership positions. Steve spent 10 years at Johnson & Johnson and 6 years at CR Bard, and was part of the senior leadership team at Zeltiq Aesthetics noted for ground breaking targeting of medical devices at consumers, with a successful IPO exit (and even more successful subsequent trade sale to Allergan). Also of note are two private equity backed leveraged management buyouts /company turnarounds, and a further two start-ups.
John is the EY MedTech leader for the Americas and is also the Life Sciences Leader for Financial and Accounting Transaction Advisory. John has over 20 years of experience, all in the healthcare industry, and originally joined E&Y in 1995.John’s corporate clients include but not limited to: Medtronic, Johnson & Johnson (including DePuy), Fresenius, GE Healthcare and Bayer, and significant PE clients including, Apax, Warburg Pincus, Avista Capital, Linden and Altaris. Prior to rejoining E&Y’s Transaction Advisory Services practice, John was CFO of a publicly traded medical technology company and was responsible for all financial and operational aspects, including capital raising and negotiating/structuring numerous collaborations and licensing arrangements, John received a B.B.A. in accounting and an M.B.A. in finance from the University of Miami.
Mr Bernasconi has more than 30 years experience in the world of pharmaceuticals and medical devices, working in companies such as Johnson & Johnson, Schering Plough in US and Europe, and more recently Medtronic.
In his capacity as President & International Regional Vice President of Medtronic France, he was elected President of APIDIM (The French Association for the Promotion of Innovation in Medical Devices), and Vice President and Treasurer of SNITEM (French Medical Technology Industry Association).
David has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover’s monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups.
Prior to joining Elsevier, David worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time.
Adelaide Cracco is the Head of Life Sciences at the European Investment Fund (EIF), institution that supports entrepreneurship and innovation across Europe, providing financing to SMEs as a cornerstone investor in venture and growth capital funds. Prior to joining the EIF, Adelaide was Managing Director of the Finaves seed capital funds based in Barcelona, where she oversaw Finaves’ investments in 20 early stage ventures and launched the firm’s fourth fund, Finaves IV.
Before working for Finaves, Adelaide was part of the founding management team and Finance Director of Mixta Africa a real estate group specialized in social and economic housing development projects with activities across the African continent and backed by Morgan Stanley and the IFC (World Bank Group). Adelaide developed most of her early career in corporate finance and private equity starting off as an analyst at the Inter-American Investment Corporation and later working for Clairfield International in Spain where she was responsible for transactions in the pharmaceutical industry, among other sectors.
Joseph Gatewood, Vice President, Global Strategy & Analysis, joined the staff of the Advanced Medical Technology Association (AdvaMed) in October 2004.
Joe has primary responsibility for AdvaMed’s policy and advocacy work in the United Kingdom, Germany, other EU-15 initial member countries, and Korea. He leads our patient and trade group advocacy in the UK and Germany. He also heads the Global Department’s efforts on global reimbursement, health technology assessment (HTA) and procurement issues, which encompasses challenges in China and other emerging markets. He leads AdvaMed’s work the EU’s regulatory reforms relating to the medical device and IVD industries. He has been engaged previously in assisting with global compliance initiatives.
Joe also worked for almost three years in the AdvaMed’s Payment and Policy Department, focusing on issues relating to the advanced wound management and orthopedic sectors, Medicare hospital inpatient services, emerging orthopedic technologies, and Medicare competitive bidding. Joe led AdvaMed’s efforts to configure and transition to MS-DRGs, as well as the initial strategic responses to Medicare competitive bidding.
Joe is an attorney who has served as a Senior Counsel for the Inspector General of the U.S. Department of Health and Human Services (HHS OIG). At HHS OIG, Joe handled enforcement, compliance and regulatory matters, including fraud and abuse and quality of care litigation. He has also worked as an attorney for the HHS Appeals Board, assisting in deciding cases relating to a variety of matters involving HHS grants and programs, including Medicare civil sanctions, exclusions and quality of care. Joe has worked for a private law firm representing clients on health care regulatory, compliance and litigation issues. He has worked outside the health care arena on government contract, compliance and ethics matters. Joe is a member of the DC and Maryland bars, and is an experienced mediator in civil litigation matters. He holds a Bachelor’s Degree from the University of Maryland, and a Juris Doctor from the Washington College of Law of The American University.
Caroline is Vice President at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Dublin office.
Prior to joining Lightstone, Caroline held the position of commercial and clinical lead on a number of early stage medical device projects and is director and founder of a start up in the healthcare IT space. Caroline has more than 10 years’ experience in the pharmaceutical industry where she held a variety of operational roles in regulatory affairs, product management, marketing and strategic business development in the oncology space. More recently Caroline held a senior management position as head of market access & reimbursement for Bayer Ltd. Ireland where she was responsible for health technology assessment applications and reimbursement negotiations with the national health services for novel drugs in the cardiovascular, oncological and hormonal therapy space.
Paul is MedTech Innovator’s CEO. He founded and has managed MedTech Innovator as a program within RCT Ventures for the past four years. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. He has spent the last 11 years as Managing Director for RCT Ventures, the investment arm of Research Corporation Technologies, Inc.
Xeltis CEO, Laurent Grandidier, has transformed Xeltis from a small research entity into one of the most promising medical device companies globally. Today, Xeltis is a clinical-stage company pioneering a revolutionary, restorative heart valve therapy. Xeltis’ devices enable the natural restoration of heart valves through a new therapeutic approach called Endogenous Tissue Restoration (ETR).
With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis’ implants are gradually absorbed by the body.
RestoreX, Xeltis’ technology platform, is the world’s first polymer-based technology for natural heart valve restoration. The technology, based on Nobel prize awarded science, has the potential to improve the lives of hundreds of thousands of patients and to reduce overall healthcare costs.
Grandidier joined Xeltis in 2011, when it was a small university spinoff. Today, the company has its first anticipated commercial product, a pulmonary valve, in clinical trials; a second product, an aortic valve, in preclinical trials; and a number of additional cardiovascular applications in its pipeline.
Grandidier successfully led Xeltis’ oversubscribed series B financing round of $30 million in 2014, extended to $33 million in 2015.
His expertise in medical devices is a result of working in leadership positions for companies such as Endosense, Guidant/Boston Scientific and Teleflex Medical.
Grandidier is co-founder of one of France’s first social venture funds, Investir&+, where he currently sits on the supervisory board. He is a board member of the Frédérique Constant Foundation, supporting pediatric clinical and research centers for treatment of children and young people with heart diseases in countries where such facilities are unavailable.
A serial entrepreneur, Jim has founded and served as CEO for four medical device start-ups and currently serves as a member of the Wallace Coulter Oversight committee where he participates in the translation of innovative technologies from the Georgia Institute of Technology and Emory University, Atlanta, Georgia into successful new commercial ventures. Additionally, he serves as Board Chairman of Novate Medical Limited, also a Seroba investee company.
As CEO and Founder of Galway-based start-up, Apica Cardiovascular, Jim developed a port access and closure system for delivering structural heart therapies which achieved CE Mark within 3 years of being established in Ireland, and which was subsequently sold to Thoratec Corporation. As CEO of APK (Advanced Medical Technologies), Atlanta, Georgia, he developed a platform technology for delivery of mechanical circulatory support systems (LVADS) for congestive heart failure patients. APK was also acquired by Thoratec Corporation. Previously, as CEO of Mitral Solutions in Fort Lauderdale, Florida, Jim steered the development of an innovative mitral valve repair device from concept through clinical trials, regulatory approval pathway and eventual sale of the company to St. Jude Medical.
Annika Grosse has been with IBM since 1997. She has a background in Business and IT Consulting, becoming an Executive Partner in 2011. Three years later, Annika began her current responsibility as Consulting Leader for Watson in Europe, now the Cognitive Health Leader in Europe.
Her industry background is primarily in Banking, Insurance, Healthcare/Life Science and Public sectors. She is passionate about successfully implementing innovative strategies and solutions that create value, as well as accompanying businesses through their transformational journey. With a masters in Computer and Information Sciences, Annika Grosse also has an M.B.A. as well as a Diploma in Strategy & Innovation from the University of Oxford.
Tim has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Proteon Therapeutics, Sientra and VirionHealth.
Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD.
Jason Hannon joined Mainstay Medical as Chief Executive Officer and as a Director in October 2017. Mr. Hannon has extensive experience in the medical devices industry, particularly in the areas most critical to the future success of Mainstay: commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management, and the building of a high-performance culture.
Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions. He helped grow NuVasive from a small U.S.-centric business with a handful of products into the third largest spine company in the world. During his 12 years at the company, and prior to becoming COO, Mr. Hannon led the international business, was responsible for business development and strategy, and also served as general counsel. During his tenure, the company’s commercial presence was expanded globally to more than 40 countries, revenue grew from $61M to almost $1 billion, and the product portfolio expanded to over 100 products.
Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.
Dr. Adam M. Hill is a senior executive within McLaren Group’s advanced technology, innovation and design company. In this role, Adam is responsible for defining growth strategy, including the incubation of McLaren’s health business.
A dual-qualified Clinician and Mechanical Engineer, Adam graduated from Imperial College London, the Royal Military Academy Sandhurst, and the Royal College of Surgeons of England. In recent the recent past, he has successfully founded an applied health research centre, advised global life science companies on behalf of the UK government, and led market access at a multinational, publicly-listed Health IT brand.
Adam has contributed to over 100 publications, 12 academic awards and patents, and is a Visiting Professor in the Institute of Global Health Innovation at Imperial College London.
Regina is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Endostim, G-Therapeutics, Themis, Rigontec, Middle Peak Medical, Ayoxxa and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GSK’s Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.
Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm, until January 2010. She was the founding investor in Bicycle Therapeutics, F-star, and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo, Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, which was acquired by SciClone (NASDAQ SCLN) in 2010.
Before, Regina worked for Apax Partners and was closely involved in investments such as Genmab and Silence Therapeutics. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000. In the 90s, Regina gained intial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK, where she collaborated with emerging UK biotech companies. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.
Paul brings over 35 years of global medical technology management experience to SV. He joined SV in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments.
Paul built and ran medical device businesses for 29 years before joining SV Health Investors. Most recently he was Chief Operating Officer at Boston Scientific (BSC), an $8 billion medical device leader. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. During his tenure, the company grew revenue over 20 times. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, Paul held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).
Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry, following Elsevier’s acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the IN3 medical device partnering conference series. Stephen joined Windhover Information in 1997, where as Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.
Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law).
Olivier Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006.
He invests primarily in European biotechnology and medtech companies as well as some investments in the United States. In addition to Endosense, he serves on the boards of Noxxon Pharma, ProBioDrug, SuperSonic Imagine, Sapiens Steering Brain Stimulation and JenaValve Technologies.
Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France). Before joining EdRIP, Litzka spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris.
In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris.
Litzka holds a Ph.D. in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and did his scientific research work over several years in Munich and Oxford.
Justin Lynch is a Partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science.
Justin began his career as a research analyst at NCB stockbrokers in 1985. During this time, Justin had analytical responsibility for 13 companies accounting for 25% of the capitalisation of the Irish Stock Exchange. In 1988, Justin joined the Corporate Finance group of Fyffes plc where his activities included the execution of a number of M&A and financial transactions. He subsequently held a similar senior Corporate Finance role with the Jones Group plc for several years before returning full time to Trinity College to complete an MBA.
After completing his MBA in 1997, Justin co-founded Legend Care and developed a series of medical hosiery devices including a preventive foot care device for diabetic foot disease which is presently in a physician led 400 patient longitudinal multi-centre RCT in the US and the UK, funded by the NIDDK, US National Institutes of Health. Justin has a particular interest in the medical device sector. He led the firms investments in Vivasure Medical and Neuravi and is a member of the board of directors of both companies.
Evan joined Abbott in 2010, as Director of Abbott Ventures and took over primary responsibility for the organization in 2014. Prior to joining Abbott, he was a Principal at ONSET Ventures.
He also held positions at Acclarent, Inc., Johnson & Johnson, Stryker Corporation, JPMorgan and PwC.
Evan attended Texas A&M University and received his Bachelor of Business Administration in Finance. He also holds a MBA from Northwestern’s Kellogg School of Management where he is an adjunct lecturer in the Kellogg Innovation and Entrepreneurship Initiative.
Daniel O’Mahony is a Partner at Seroba Life Sciences and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.
Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He was an advisor and consultant to Kernel Capital venture capital fund from 2001 and a partner from 2008, focusing on investments in life sciences. He joined Seroba as partner in 2009.
Daniel graduated with a Ph.D. from the National University of Ireland, Cork in 1986 and holds a business degree in technology management from the Smurfit Business School, University College Dublin (2000). He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at University College Dublin. He has published in several scientific journals and is co-inventor on numerous patent families.
Dr O’Mahony currently sits on the board of Atlantic Therapeutics, MedLumics, Novate Medical and PQ Bypass. He previously sat on the boards of Apica Cardiovascular (acquired by Thoratec), Covagen (acquired by Cilag/Janssen Pharmaceutical Companies of the Johnson & Johnson Group), Stokes Bio (acquired by Life Technologies), Straatum (acquired by Lam Research Corporation).
Stan Rabinovich currently serves as Vice President, Advanced Technology at Edwards Lifesciences. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technologies, Inc. (PVT) of which he was co-founder, Executive Vice President and COO. PVT has pioneered the development of transcatheter heart valves.
Prior to PVT, Stan was Corporate Director of Business Development for Datascope Corp. Prior to that, Stan spent over 17 years of his medical device development career at Johnson & Johnson, where he held positions in Engineering, R&D and Business Development at Johnson & Johnson Interventional Systems JJIS), SITE Microsurgical and Johnson & Johnson Ultrasound. While at JJIS, Stan broke new ground in a stent fabrication process utilizing laser technology and originated manufacturing of self-expanding stents made from nitinol tubing.
Stan graduated from Riga Polytechnic Institute, Latvia and holds a Master’s degree in Electrical Engineering.
Since January 2007, Mr. Rasche has been a partner at Earlybird Venture Capital, a venture capital firm, where he previously served as a Venture Partner from July 2003 to December 2006.
Prior to joining Earlybird, Mr. Rasche was the Managing Director for ETHICON Endo-Surgery, a division of ETHICON GmbH (a Johnson & Johnson company), from January 2000 to June 2003.
Mr. Rasche holds a Degree as Diplom Kaufmann (M.B.A. equivalent) from the University of Applied Sciences in Lüneburg, Germany, specializing in Marketing and Human Resource Management.
Josep L.l. Sanfeliu focuses on medtech investments and on structuring transactions.
Josep serves on the board of MedLumics, Dermalumics,CVRx , Corwave, Anaconda Biomed, Babyscripts and Xeltis. Formerly, he was board observer at Endosense and board member at Sabir Medical.
Josep has over 15 years of experience in law, corporate finance and business development in connection with entrepreneurs and with intellectual property related companies. Before joining Ysios, Josep worked for the pharma and healthcare industries, in areas such as business and corporate development. This included managerial positions at Almirall and SAR-Quavitae. Joe also worked at Cuatrecasas, KPMG and Eurohold Corporate Finance, where he was involved in mergers and acquisitions, and financing of innovation and technology.
Josep holds a degree in Law from Universitat Pompeu Fabra of Barcelona, a Master of Laws (LL.M) degree from the University of Michigan at Ann Arbor, and an MBA (Global Executive MBA) from IESE (University of Navarra).
Prior to founding SHS, spent eight years as management consultant with McKinsey & Co. Inc., most recently as senior engagement manager. Studied economics at Albert Ludwig University in Freiburg, Germany and the London School of Economics.
Chas has over 20 years’ experience in the medical device industry. He has been involved in successful medical device start-up companies since 1996. He co-founded embolic filter and carotid stent specialists MedNova which was acquired by Abbott in 2005. Before this he worked with CR Bard for twelve years in various sales, marketing and general management roles. During this time he was based in the USA for eight years in senior positions including Vice-President for Bard Cardiovascular.